Safety and Immunogenicity of the MVA85A Tuberculosis Vaccine in West Africa
Author Information
Author(s): Brookes Roger H., Hill Philip C., Owiafe Patrick K., Ibanga Hannah B., Jeffries David J., Donkor Simon A., Fletcher Helen A., Hammond Abdulrahman S., Lienhardt Christian, Adegbola Richard A., McShane Helen, Hill Adrian V. S.
Primary Institution: Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia
Hypothesis
Can the MVA85A vaccine induce a strong immune response in West African volunteers?
Conclusion
The MVA85A vaccine is safe and highly immunogenic in West African volunteers.
Supporting Evidence
- MVA85A was well tolerated with no significant adverse events.
- Marked immunogenicity was found regardless of prior BCG vaccination status.
- Responses were predominantly attributable to CD4+ T cells, with some CD8+ T cell responses identified.
Takeaway
The MVA85A vaccine is like a superhero shot that helps your body fight off tuberculosis, and it worked well in people from West Africa.
Methodology
21 healthy adult males were vaccinated with MVA85A and monitored for immune responses and adverse events over six months.
Potential Biases
Potential bias due to the limited demographic of participants.
Limitations
The study had a small sample size and was limited to healthy adult males.
Participant Demographics
21 healthy adult males, 11 BCG scar negative and 10 BCG scar positive.
Statistical Information
P-Value
p=0.002
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website